Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01120379 · ClinicalTrials.gov registry record

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

A clinical trial of Coronary Artery Disease and Coronary Disease, sponsored by Abbott Medical Devices.

Completed
Registry status
5,034
Enrollment target
1
Study location

NCT01120379: Completed study of Coronary Artery Disease and Coronary Disease, sponsored by Abbott Medical Devices.

NCT01120379 is a study of Coronary Artery Disease and Coronary Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 5,034 participants, above the 1,264-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (298% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01120379, a study of Coronary Artery Disease and Coronary Disease, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
5,034 participants
Enrollment target
1
Study location

Study Summary

XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.

Primary Outcome

Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to docum

Conditions Studied

Coronary Artery Disease Coronary Disease Myocardial Ischemia Vascular Disease Coronary Artery Stenosis Coronary Restenosis Chronic Coronary Occlusion

Interventions

  • DEVICE XIENCE V® EECSS

Study Locations (1)

California

  • Abbott Vascular - Santa Clara

Trial Details

FieldValue
Enrollment Target 5,034 participants
Start Date 2008-07
Est. Completion 2013-12
Abbott Medical Devices

261 total trials

What the finished NCT01120379 record still lists

NCT01120379 is an observational study that tracks outcomes without assigning an intervention. Its 5,034 participants enrollment target places it among the larger protocols in the corpus, above the 1,264-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (298% higher).

The record links to 7 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which XIENCE V® EECSS is the first listed.

NCT01120379 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01120379 about?

NCT01120379 is a clinical study titled "XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)". XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet the...

What is the current status of trial NCT01120379?

This trial is currently completed. The enrollment target is 5,034 participants. The study started on 2008-07. Estimated completion is 2013-12.

What conditions does trial NCT01120379 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Vascular Disease, Coronary Artery Stenosis.

What interventions are being tested in trial NCT01120379?

The interventions under investigation include: XIENCE V® EECSS (DEVICE).

Who is sponsoring clinical trial NCT01120379?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01120379 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01120379's enrollment target sits among peer trials

5,034 12th of 219 higher than 208 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07037459 · 5,056 participants · Phase 3

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • NCT04743362 · 5,010 participants

    A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01120379, the US trial registry maintained by the National Library of Medicine. NCT01120379 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.